Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
NNOX · Nasdaq · United States · X-Ray Apparatus & Tubes & Related Irradiation Apparatus
In shortNano-X Imaging Ltd. is loss-making, burns cash and holds more cash than debt, with revenue growing (+15.4% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -600.8% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -576.1% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -45.6% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -53.4% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.96× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.02× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -3.70 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -345.6% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 4 | 100/100 |
| Revenue growth volatility | 271.4% | 0/100 |
| Operating margin volatility | 1797.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 14.9% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
3 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1.3 | 8.6 | 9.9 | 11 | 13 |
| Cost of revenue | 2.8 | 15 | 16 | 22 | 26 |
| Gross profit | (1.5) | (6.9) | (6.6) | (11) | (13) |
| Research & development | 17 | 27 | 26 | 20 | 19 |
| Operating income | (62) | (118) | (63) | (57) | (78) |
| Pre-tax income | (62) | (117) | (61) | (54) | (77) |
| Income tax | (0) | (3.7) | (0.3) | (0.4) | (1.8) |
| Net income | (62) | (113) | (61) | (54) | (75) |
| Diluted EPS | −$1.28 | −$2.17 | −$1.08 | −$0.91 | −$1.16 |
| Diluted shares (millions) | – | 52 | 0.1 | 0.1 | 0.1 |
3 older years available with the 10-year history. Essential plan, from €8.25/month →
−3.70 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 30, 2026